25 June 2020 : Database Analysis
Effects of Marital Status on Prognosis in Women with Infiltrating Ductal Carcinoma of the Breast: A Real-World 1: 1 Propensity-Matched Study
Tian Lan1ABCDEF*, Yunyan Lu2BCD, Hua Luo1CD, Junling He1BE, Jiawei He1CF, Zujian Hu1EF, Haibin Xu1ADOI: 10.12659/MSM.923630
Med Sci Monit 2020; 26:e923630
Table 3 Impact of marital status on the BCSS by univariate and multivariate survival analysis before PSM.
| Characteristics | 5-year OS | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| Log rank χ2 | P value | HR | 95% CI | P value | ||
| Marital status | 1200.1 | <0.001 | ||||
| Married | 92.9% | Reference | ||||
| Divorced | 90.2% | 1.15 | 1.09–1.21 | <0.001 | ||
| Single | 87.6% | 1.27 | 1.21–1.33 | <0.001 | ||
| Widowed | 86.4% | 1.32 | 1.25–1.40 | <0.001 | ||
| Age | 1228.9 | <0.001 | ||||
| 18–49 | 90.6% | Reference | ||||
| 50–59 | 91.4% | 2.04 | 1.93–2.15 | <0.001 | ||
| 60–69 | 92.9% | 1.34 | 1.29–1.40 | <0.001 | ||
| 70–79 | 91.0% | 1.08 | 1.03–1.12 | <0.001 | ||
| ≥80 | 82.7% | 0.96 | 0.92–1.00 | 0.040 | ||
| Race | 1194.6 | <0.001 | ||||
| White | 91.6% | Reference | ||||
| Black | 83.8% | 1.27 | 1.21–1.33 | <0.001 | ||
| API | 93.6% | 0.8 | 0.74–0.86 | <0.001 | ||
| AI | 89.5% | 1.27 | 1.03–1.57 | 0.026 | ||
| Gender | 23.2 | <0.001 | ||||
| Male | 86.5% | Reference | ||||
| Female | 90.9% | 0.88 | 0.74–1.05 | 0.145 | ||
| Median household income | 468.0 | <0.001 | ||||
| Quartile 1 | 88.7% | Reference | ||||
| Quartile 2 | 90.3% | 0.80 | 0.77–0.84 | <0.001 | ||
| Quartile 3 | 91.8% | 1.00 | 0.97–1.04 | 0.846 | ||
| Quartile 4 | 93.0% | 1.04 | 1.00–1.07 | 0.067 | ||
| Insurance | 304.8 | <0.001 | ||||
| Uninsured | 81.3% | Reference | ||||
| Insured | 91.1% | 0.74 | 0.67–0.81 | <0.001 | ||
| Grade | 5565.4 | <0.001 | ||||
| I | 98.2% | Reference | ||||
| II | 93.7% | 2.01 | 1.82–2.22 | <0.001 | ||
| III | 83.9% | 3.71 | 3.36–4.10 | <0.001 | ||
| Stage | 38639.6 | <0.001 | ||||
| I | 97.9% | Reference | ||||
| II | 91.2% | 2.93 | 2.74–3.12 | <0.001 | ||
| III | 75.2% | 8.98 | 8.37–9.63 | <0.001 | ||
| IV | 35.7% | 24.52 | 22.72–26.47 | <0.001 | ||
| Subtype | 4705.1 | <0.001 | ||||
| HR−/HER2− (triple negative) | 79.1% | Reference | ||||
| HR−/HER2+ (HER2 enriched) | 85.6% | 0.43 | 0.40–0.47 | <0.001 | ||
| HR+/HER2− (Luminal A) | 93.5% | 0.41 | 0.39–0.43 | <0.001 | ||
| HR+/HER2+ (Luminal B) | 90.9% | 0.32 | 0.30–0.34 | <0.001 | ||
| Surgery | 19591.4 | <0.001 | ||||
| No surgery | 51.9% | Reference | ||||
| BCS | 95.7% | 0.33 | 0.31–0.36 | <0.001 | ||
| Mastectomy | 88.7% | 0.45 | 0.42–0.47 | <0.001 | ||
| Radiation | 922.3 | <0.001 | ||||
| None/unknown | 88.5% | Reference | ||||
| Yes | 92.8% | 0.86 | 0.82–0.89 | <0.001 | ||
| Chemotherapy | 1605.0 | <0.001 | ||||
| No/unknown | 94.0% | Reference | ||||
| Yes | 87.3% | 0.85 | 0.82–0.90 | <0.001 | ||
| BCSS – breast cancer-specific survival; PSM – propensity score matching; HR – hazard ratio; CI – confidence interval. | ||||||